A Phase 1b/2 Trial of AMG 655 in Combination With Panitumumab in Subjects With Metastatic Colorectal Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 02 Apr 2014
At a glance
- Drugs Conatumumab (Primary) ; Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 31 Aug 2018 Biomarkers information updated
- 05 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 Jul 2010 Planned end date changed from 1 Jan 2010 to 1 Nov 2011 as reported by ClinicalTrials.gov.